(Boursier.com) — Up 1.7% to 91.7 euros, Sanofi clearly outperformed the market on Friday. It must be said that the laboratory has received good news from the United States insofar as the FDA has approved ALTUVIIIO, a factor VIII administered once a week for patients with hemophilia A. “ALTUVIIIO is the first and only treatment of hemophilia A that achieves normal or near-normal (greater than 40%) factor activity levels for most of the week, at a weekly dose, and significantly reduces bleeding compared to previous prophylactic treatment with factor VIII”, specifies Sanofi.
Hemophilia A is an inherited bleeding disorder that results in the inability of blood to clot properly.
Oddo BHF is not modifying its ‘outperformance’ recommendation following this announcement and even believes that this approval could reassure the market in part as to the group’s ability to innovate. In the short term, the market and the analyst will still focus on the results expected in the coming weeks from Dupixent in the COPD. The difficulty of this indication (there have been many failures) calls for caution, but the reward risk seems appropriate. As a reminder, the target population here is patients with an eosinophilic type 2 inflammatory component (approximately 30/40% of the population). The improvement in lung function (FEV1) in his trial in asthma suggests a probability of success (modeled 60% vs 40% for Cs) although the latter population was excluded from the trial in the COPD, says the analyst.
©2023 Boursier.com